Table 2 Antimicrobial agents used for susceptibility testing of Salmonella isolates, 2014–2021
WHO category level | Importance | Antimicrobial Class | Antimicrobial Agent | Years Tested | Antimicrobial Agent Concentration Range (μg/mL) | MIC Interpretive Standard (µg/mL) | ||
|---|---|---|---|---|---|---|---|---|
Susceptible (S) | Intermediate (I) | Resistant (R) | ||||||
I | Critically importanta | Cephalosporins (3rd,4th and 5th generation) | Cefotaxime (CTX) | 2014–2021 | 0.25 ~ 8 | 1 | 2 | 4 |
Ceftazidime (CAZ) | 2014–2021 | 1 ~ 32 | 4 | 8 | 16 | |||
Macrolides | Azithromycin (AZM) | 2015–2021 | 4 ~ 64 | 16 | - | 32 | ||
Polymyxins | Colistin E (CT) | 2019–2021 | 0.12 ~ 4 | 2 | - | 4 | ||
Quinolones | Nalidixic acid (NAL) | 2014–2021 | 2 ~ 64 | 16 | - | 32 | ||
Ciprofloxacin (CIP) | 2014–2021 | 0.03 ~ 32 | 0.06 | 0.125 ~ 0.5 | 1 | |||
Aminoglycosides | Gentamicin (GEN) | 2014–2021 | 1 ~ 32 | 4 | 8 | 16 | ||
Carbapenems | Imipenem (IPM) | 2015–2021 | 0.25 ~ 8 | 1 | 2 | 4 | ||
Penicillins | Ampicillin (AMP) | 2014–2021 | 2 ~ 64 | 8 | 16 | 32 | ||
Penicillins (with β-lactamase inhibitors) | Ampicillin/sulbactam (AMS) | 2015–2021 | 2/1 ~ 64/32 | 8/4 | 16/8 | 32/16 | ||
II | Highly important | Cephalosporins (1st and 2nd generation) and Cephamycins | Cefazolin (CFZ) | 2015–2021 | 0.5 ~ 16 | 2 | 4 | 8 |
Cefoxitin (CFX) | 2015–2021 | 2 ~ 64 | 8 | 16 | 32 | |||
Phenicols | Chloramphenicol (CHL) | 2014–2021 | 2 ~ 64 | 8 | 16 | 32 | ||
Tetracyclines | Tetracycline (TET) | 2014–2021 | 1 ~ 32 | 4 | 8 | 16 | ||
Folate pathway inhibitors | Trimethoprim-sulfamethoxazole (SXT) | 2015–2021 | 0.25/4.75 ~ 8/152 | 2/38 | - | 4/76 | ||